Compare CKX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | BCDA |
|---|---|---|
| Founded | 1930 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 17.9M |
| IPO Year | 1996 | N/A |
| Metric | CKX | BCDA |
|---|---|---|
| Price | $11.06 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 10.2K | ★ 6.2M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $838,543.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $368.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $0.78 |
| 52 Week High | $13.00 | $2.45 |
| Indicator | CKX | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 64.58 |
| Support Level | $11.03 | $1.11 |
| Resistance Level | $11.76 | $1.34 |
| Average True Range (ATR) | 0.60 | 0.11 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 33.60 | 87.10 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).